Wenling City Innovation Biopharmaceutical Technology

Wenling City Innovation Biopharmaceutical Technology Co., Ltd. is a Chinese pharmaceutical company established in 2019 and based in Wenling, Zhejiang Province. Operating primarily under the Marketing Authorization Holder (MAH) system, the company focuses on the research, development, and commercialization of innovative drugs and high-end generic pharmaceuticals. It leverages contract development and manufacturing organizations (CDMOs) and pharmaceutical partners, such as Wanbangde Pharmaceutical Group and Jiangsu Zhongxing Pharmaceutical, to manufacture its products. The company's commercial portfolio and pipeline include small molecule therapeutics across various therapeutic areas, including anti-infectives, respiratory diseases, antiviral treatments, and metabolic disorders like gout.